Circulating Anti-GB3 Antibody as a Biomarker of Myocardial Inflammation in Patients with Fabry Disease Cardiomyopathy.
Fabry disease
cardiac biopsy
globotriaosylceramide
inflammation
myocarditis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
15 Jun 2023
15 Jun 2023
Historique:
received:
06
04
2023
revised:
31
05
2023
accepted:
13
06
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Fabry disease cardiomyopathy (FDCM) has manifested some resistance to enzyme replacement therapy (ERT), particularly in its advanced phase. Recently, myocardial inflammation of autoimmune origin has been demonstrated in FDCM. The objective of this study was the assessment of circulating anti-globotriaosylceramide (GB3) antibodies as potential biomarkers of myocardial inflammation in FDCM, defined by the additional presence of ≥CD3+ 7 T lymphocytes/low-power field associated with focal necrosis of adjacent myocytes. Its sensitivity was based on the evidence of overlapping myocarditis at left ventricular endomyocardial biopsy. From January 1996 to December 2021, 85 patients received a histological diagnosis of FDCM in our department and 48 (56.5%) of them had an overlapping myocardial inflammation with negative PCR for common cardiotropic viruses, positive antiheart, and antimyosin abs. The presence of anti-GB3 antibodies was evaluated with an in-house ELISA assay (BioGeM scarl Medical Investigational Research, MIR-Ariano Irpino, Italy), along with antiheart and antimyosin abs, in the FDCM patients and compared with control healthy individuals. The correlation between levels of circulating anti-GB3 autoantibody myocardial inflammation and FDCM severity was assessed. Anti-Gb3 antibodies were above the positivity cut-off in 87.5% of FDCM subjects with myocarditis (42 out of 48), while 81.1% of FDCM patients without myocarditis were identified as negative for Gb3 antibodies. Positive anti-Gb3 abs correlated with positive antiheart and antimyosin abs. The present study suggests a potential positive role of anti-GB3 antibodies as a marker of overlapping cardiac inflammation in patients with FDCM.
Sections du résumé
BACKGROUND
BACKGROUND
Fabry disease cardiomyopathy (FDCM) has manifested some resistance to enzyme replacement therapy (ERT), particularly in its advanced phase. Recently, myocardial inflammation of autoimmune origin has been demonstrated in FDCM.
AIMS
OBJECTIVE
The objective of this study was the assessment of circulating anti-globotriaosylceramide (GB3) antibodies as potential biomarkers of myocardial inflammation in FDCM, defined by the additional presence of ≥CD3+ 7 T lymphocytes/low-power field associated with focal necrosis of adjacent myocytes. Its sensitivity was based on the evidence of overlapping myocarditis at left ventricular endomyocardial biopsy.
METHODS AND RESULTS
RESULTS
From January 1996 to December 2021, 85 patients received a histological diagnosis of FDCM in our department and 48 (56.5%) of them had an overlapping myocardial inflammation with negative PCR for common cardiotropic viruses, positive antiheart, and antimyosin abs. The presence of anti-GB3 antibodies was evaluated with an in-house ELISA assay (BioGeM scarl Medical Investigational Research, MIR-Ariano Irpino, Italy), along with antiheart and antimyosin abs, in the FDCM patients and compared with control healthy individuals. The correlation between levels of circulating anti-GB3 autoantibody myocardial inflammation and FDCM severity was assessed. Anti-Gb3 antibodies were above the positivity cut-off in 87.5% of FDCM subjects with myocarditis (42 out of 48), while 81.1% of FDCM patients without myocarditis were identified as negative for Gb3 antibodies. Positive anti-Gb3 abs correlated with positive antiheart and antimyosin abs.
CONCLUSIONS
CONCLUSIONS
The present study suggests a potential positive role of anti-GB3 antibodies as a marker of overlapping cardiac inflammation in patients with FDCM.
Identifiants
pubmed: 37373761
pii: jcm12124068
doi: 10.3390/jcm12124068
pmc: PMC10299309
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Mol Genet Metab. 2017 Nov;122(3):19-27
pubmed: 28947349
J Am Heart Assoc. 2018 Sep 4;7(17):e009052
pubmed: 30371172
Circulation. 2000 Dec 19;102(25):3060-7
pubmed: 11120695
J Am Heart Assoc. 2018 Nov 6;7(21):e009098
pubmed: 30571380
JIMD Rep. 2015;22:1-10
pubmed: 25690728
Biochim Biophys Acta. 2012 Feb;1822(2):226-32
pubmed: 22085605
Lancet. 2008 Oct 18;372(9647):1427-35
pubmed: 18940466
Contrib Nephrol. 2001;(136):174-92
pubmed: 11688379
Orphanet J Rare Dis. 2010 Nov 22;5:30
pubmed: 21092187
J Intern Med. 2013 Oct;274(4):331-41
pubmed: 23586858
Mol Genet Metab. 2011 Nov;104(3):319-24
pubmed: 21724436
Orphanet J Rare Dis. 2013 Mar 25;8:47
pubmed: 23531228